CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced that new data from its collaborations with multiple academic medical center research groups will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) taking place December 4-8, 2012 in San Antonio, Texas. These presentations highlight Foundation Medicines targeted next-generation sequencing platform for comprehensive molecular profiling in cancer.

Foundation Medicines core commitment is towards a transformation in cancer care, where each patients treatment is informed by a deep understanding of the genomic and other molecular changes that contribute to their disease, said Gary Palmer, M.D., J.D., senior vice president, medical affairs, Foundation Medicine. These new data, presented with our collaborators at SABCS, provide oncology thought leaders with new, deeper insight into the molecular drivers of breast cancer. We feel these findings will accelerate advances in patient care.

The schedule for Foundation Medicines presentations is as follows:

Date & Time: Wednesday, December 5, 2012 at 5:00 p.m. CT

Title: Next-generation sequencing of FFPE breast cancers demonstrates high concordance with FISH in calling HER2 amplifications and commonly detects other clinically relevant genomic alterations

Abstract: PD02-07

Session: Poster Discussion 2 HER2

Location: Ballroom B

Presenter: Doron Lipson, Foundation Medicine (research in collaboration with Albany Medical College)

Go here to see the original:

New Clinical Data Highlighting Foundation Medicine’s Next-Generation Sequencing Analysis in Breast Cancer to be ...